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Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory cytokine produced 
by macrophages and T-cells. It plays an important role both in inflammation and 
apoptosis. In the eye, TNF-α appears to have a role in the pathogenesis of inflammatory, 
edematous, neovascular and neurodegenerative disorders. Several TNF-blocking 
drugs have been developed and approved, and are in clinical use for inflammatory 
diseases such as rheumatoid arthritis, psoriasis and ankylosing spondylitis. TNF-α 
blockers are widely used in ophthalmology as an off-label alternative to “traditional” 
immunosuppressive and immune-modulatory treatments in noninfectious uveitis. 
Preliminary studies suggest a positive effect of intravenously administered TNF-α 
blockers, mainly infliximab, for treating refractory diabetic macular edema and 
neovascular age-related macular degeneration. Unfortunately, much of the current 
data raises considerable safety concerns for intravitreal use of TNF-α inhibitors, in 
particular, intraocular inflammatory responses have been reported after intravitreal 
injection of infliximab. Results of dose-finding studies and humanized antibody or 
antibody fragments (e.g. adalimumab) are anticipated in the coming years; these will 
shed light on potential benefits and risks of local and systemic TNF-α blockers used 
for treatment of diseases of the retina and choroid.
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INTRODUCTION
The tumor necrosis factor alpha (TNF-α) belongs 
to the group of pro-inflammatory cytokines 
produced by macrophages and T-cells and 
plays an important role in inflammation and 
apoptosis.1 Cytokines have a key function in 
establishing and sustaining acute and chronic 
inflammation. In several rheumatic diseases (e.g. 
rheumatoid arthritis, ankylosing spondylitis), 
TNF-α concentration is elevated in affected 
joints, which seems to play a prominent role 
in joint destruction. Similarly, overproduction 
of TNF-α has also been observed in Crohn’s 
disease and psoriasis arthritis.
In the eye, TNF-α appears to participate in 
the pathogenesis of inflammatory, edematous, 
neovascular, and neurodegenerative diseases.2 
Injection of TNF-α into animal eyes induces 
breakdown of the blood–retina barrier.3 
Furthermore, increased levels of TNF-α and 
TNF-receptors have been found in serum of Anti-TNF-α Therapy for Retinal Diseases; Mirshahi et al
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humans with uveitis.2 Upregulation of TNF-α 
expression has been shown in keratocytes of 
patients with rheumatoid corneal ulcerations.4 
Moreover, there is increasing evidence on TNF-α 
involvement in the pathogenesis of experimental 
retinal neovascularization, proliferative 
vitreoretinopathy, and macular edema.5-7 In an 
in vivo animal model of retinal injury, Berger 
et al showed that TNF-α plays a deleterious 
role in ischemia-reperfusion injury. Direct 
neutralization of this cytokine partially preserved 
retinal function.8 The diverse characteristics of 
TNF-α were attributed in part to the timing of its 
expression after injury. In their experimental study, 
Nagineti et al demonstrated that inflammatory 
cytokines, including interleukin 1 beta (IL-1β), 
interferon gamma (IFN-γ) and TNF-α, increase 
the secretion of vascular endothelial growth 
factor (VEGF) A and C by human retinal pigment 
epithelial (RPE) cells and choroidal fibroblasts, 
with VEGF being the most important factor for 
initiating pathological ocular neovascularization.9 
TNF-α appears to play a major role in the 
pathogenesis of diabetic retinopathy in rats, 
and its pharmacological blocking leads to the 
inhibition of retinal cell death.10
In the 1990’s, pharmaceutical companies 
succeeded in developing drugs that neutralize 
TNF-α, i.e. TNF-α blockers. These agents were 
expected to have a positive effect on reducing 
symptoms of various diseases associated 
with increased TNF-α activity.11 The first 
TNF-α blockers were approved for therapy of 
rheumatoid arthritis in 1998. Several other TNF-α 
blockers have been developed and approved 
since then for other diseases, e.g. ankylosing 
spondylitis and psoriasis.
Currently available TNF-α blockers on the 
market include the following:
Infliximab (Remicade®), a chimeric human 
immunoglobulin G1 (IgG1) with a mouse 
variable fragment (Fv) having high TNF-α 
affinity and neutralizing capacity.
Adalimumab (Humira®), a fully humanized 
antibody against TNF-α.
Etanercept (Enbrel®), a recombinant dimeric 
protein generated by fusion of the ligand-
binding portion of human type 2 TNF receptor 
(TNFR-2) linked to the fragment crystallizable 
(Fc) portion of human IgG1.
Certolizumab pegol (Cimzia®), a PEGylated 
humanized anti-TNF fragment antigen binding 
(Fab).
Golimumab (Simponi®), a human anti-
TNF-α IgG1κ monoclonal antibody.
Since their introduction, ophthalmologists 
have used TNF-α blockers to treat several 
ocular diseases “off-label”. While most of the 
data now available addresses the treatment of 
uveitis, interesting new papers have focused on 
neovascular age-related macular degeneration, 
diabetic macular edema and retinal vein 
occlusions.
SySTEMIC ADMINISTRATION OF ANTI-
TNF AgENTS FOR OCULAR DISEASES
The anti-inflammatory effects of TNF-α blockers 
make them an obvious therapeutic alternative 
for noninfectious ocular inflammation, especially 
when more conventional glucocorticoid or 
antimetabolite therapy has failed to control the 
inflammation, or their chronic use produces 
unwanted side effects. Treatment of any 
ocular disease with TNF-α blockers should 
be considered off-label, and it is advisable to 
obtain informed written consent.12, 13
Petropoulos et al reported 15 patients (28 
eyes of 7 men and 8 women) with chronic, 
refractory, noninfectious uveitis receiving 
systemic anti-TNF-α therapy as single or 
adjunctive therapy.14 Ten patients had 
primary or secondary involvement of the 
posterior segment. All patients demonstrated 
improvement on fluorescein angiography (FA) 
and optical coherence tomography (OCT) as 
well as stable or improved visual acuity within 
the first two months after initiating anti-TNF-α 
therapy with infliximab (n=8) or adalimumab 
(n=2). No recurrence was observed and patients’ 
self-assessment of the effect of therapy was 
positive in all cases. Only one patient with 
retinal vasculitis associated with Crohn’s 
disease experienced serious side effects (arterial 
hypotension, fatigue, gastric symptoms).
In a comparative study of patients with retinal 
vasculitis due to Behçet’s disease, the infliximab 
treatment group (n=10) showed a significant Anti-TNF-α Therapy for Retinal Diseases; Mirshahi et al
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decrease in inflammation, improvement in 
visual acuity and reduced ocular complications 
compared to the conventional therapy group 
(n=33).15 Moreover, the number of relapses was 
significantly less in the infliximab group than in 
the conventional group, i.e. 1.2 versus 6.3 relapses.
Diaz-Llopis et al presented outcomes of 
therapy in 19 patients with refractory uveitis 
including 33 eyes with cystoid macular edema 
(CME).16 After one year of treatment with 
adalimumab, 54.5% of eyes demonstrated 
complete resolution of CME and 31% had an 
improvement in visual acuity by 0.3 logMAR.
Systemic administration of infliximab 
(Remicade®) is by intravenous infusion and is 
usually started with a loading dose at initiation of 
treatment and two weeks thereafter. Maintenance 
treatment is administered at 4 to 6 week intervals. 
Inflammatory activity usually diminishes within 
12 weeks after initiating treatment, otherwise 
such treatment should be reconsidered.
Adalimumab (Humira®) is administered 
by subcutaneous injections with single 40 mg 
doses at biweekly intervals. A loading dose may 
be given up to 160 mg (4 injections on the first 
day of treatment), when inflammatory disease 
activity must be quickly reduced. Should the 
response be insufficient, treatment may be 
increased to weekly injections.
Etanercept (Enbrel®) is usually injected 
subcutaneously at a 25 mg dose twice a week 
or as a single subcutaneous injection 50 mg per 
week.
Certolizumab pegol (Cimzia®) is available 
in preloaded syringes containing 200 mg for 
subcutaneous injection. A loading dose of 400 
mg (i.e. two injections on the same day) is 
recommended at weeks 0, 2 and 4. Injections 
of 200 mg are administered biweekly thereafter.
Golimumab (Simponi®) is also available in 
preloaded syringes for subcutaneous injection. 
These syringes contain 50 mg of the agent and 
injections are given once monthly. In patients 
weighing over 100 kg and unresponsive to 
treatment after 3 to 4 months, the dosage may 
be increased to 100 mg (two syringes on a single 
day) once a month.
Since the immune system may produce 
antibodies against any administered TNF-α 
inhibitor, its therapeutic efficacy may diminish 
over time. When that happens, switching to 
another TNF-α blocker may be considered, 
however, the efficacy and side-effects of the 
second drug must be monitored meticulously.
Complications and adverse reactions
The most severe side effects of TNF blockers 
are due to increased susceptibility to infectious 
diseases, most notably tuberculosis and other 
respiratory tract infections and gastrointestinal 
infections, e.g. hepatitis B reactivation.
Immune-mediated side effects may 
also occur such as atopic dermatitis, rash, 
hypersensitivity types I, II, III, lupus-like 
reactions and exacerbation of autoimmune 
diseases (e.g. multiple sclerosis). Other reported 
side effects include thromboembolic disorders, 
congestive heart failure, and malignancies, 
especially lymphomas and skin tumors.
Systemic use of TNF blockers for diseases 
other than noninfectious uveitis
In 2005, Markomichelakis et al reported three 
cases of CNV regression secondary to age-related 
macular degeneration in patients under systemic 
administration of infliximab for inflammatory 
arthritis.17 The arthritis and neovascular age-
related macular degeneration happened to 
coincide in these patients. An increase in visual 
acuity (VA) was observed in all three patients; 
improvement in one of them lasted for 18 
months. In a recent prospective randomized 
study, Sfikakis and coworkers treated 11 patients 
with diabetic macular edema refractory to laser 
treatment with either intravenous infliximab 
(5 mg/kg) at weeks 0, 2, 6, and 14, followed 
by placebo at weeks 16, 18, 22, and 30, or vice-
versa.18 VA improved significantly in 8 eyes of 
the immediate infliximab group, and this effect 
was sustained during the placebo phase. The 
authors suggest a larger trial to shed light on 
the efficacy of local or systemic TNF-blocking 
therapy in diabetic macular edema. Given that 
the treatment of refractory diabetic macular 
edema is challenging,19 results of this study 
may lead to the evolution of a new treatment Anti-TNF-α Therapy for Retinal Diseases; Mirshahi et al
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modality for this sight-threatening disease.
These observations, together with the 
hypothesis that TNF-α may play a decisive 
pathogenetic role in the development of 
neovascularization in the eye, are leading to 
the development of animal models and human 
studies on intravitreal application of anti-TNF 
drugs in vascular and neovascular diseases of 
the retina and choroid.
INTRAvITREAL INjECTION OF ANTI-TNF 
AgENTS FOR RETINAL DISEASES
Systemic TNF-α inhibitors are established drugs 
for therapy of rheumatic and auto-immune 
diseases, and positive effects have been observed 
in concurrent retinal and inflammatory eye 
diseases. The particular nature of ocular diseases, 
i.e. being restricted to ocular tissues, allows use 
of the vitreous cavity as a drug reservoir. Thus 
attempts to inject TNF-α inhibitors intravitreally 
(as routinely performed with anti-VEGF agents) 
is the next step. Anticipated advantages include 
bypassing the notorious side effects of systemic 
TNF-α inhibitors and achieving higher local 
concentrations.
Two current studies investigated the 
human vitreous for inflammatory mediators. 
Yoshimura et al collected vitreous specimens 
from 345 eyes with several retinal diseases such 
as diabetic retinopathy (DR), central retinal 
vein occlusion (CRVO), rhegmatogenous retinal 
detachment, and diabetic macular edema; they 
did not observe an elevated concentration of 
TNF-α in any of these disorders as compared 
to the control group (patients with idiopathic 
macular hole or macular pucker)20, but they 
did detect elevated concentrations of IL-6, IL-8 
and monocyte chemoattractant protein-1 (MCP-
1). Contradictory to their study, Suzuki et al 
analyzed the expression profile of cytokines in 
the vitreous fluid of 86 patients with DR (n=76) 
and CRVO (n=10), noting a significantly higher 
concentration of TNF-α in the vitreous of CRVO 
patients (234.9 pg/ml versus 158.11 pg/ml) 21. 
However, they also measured significantly higher 
concentrations of IL-8, IL-10, IL-13, immune-
protein 10 (IP-10; interferon inducible protein-10), 
MCP-1, macrophage inflammatory protein-1 beta 
(MIP-1β) and VEGF in both conditions. Moreover, 
through a VEGF correlation analysis they found 
that anti-inflammatory cytokines such as IL-10 
and IL-13 may be involved in the pathogenesis 
of DR and CRVO. These studies do not support 
the hypothesis that TNF-α plays a major role 
in primary non-inflammatory retinal diseases, 
however it may be that the choroid or retina 
themselves are the locus of increased TNF-α 
concentration, not the vitreous body.
In light of these results, it is not surprising 
that results of intravitreally administered TNF-α 
inhibitors are so heterogeneous. Wu and coworkers 
performed an interventional, multicenter 
retrospective study on diabetic macular edema.22 
They treated 39 eyes with intravitreal adalimumab 
2 mg/0.1 ml (n=5), infliximab 1mg/0.05 ml (n=15) 
or infliximab 2mg/0.1 ml (n=19). All patients had 
received at least three injections of VEGF inhibitors 
before. VA did not increase significantly in either 
the adalimumab or the 1mg infliximab group after 
three months; in the 2 mg infliximab group it 
even deteriorated. The authors also investigated 
macular thickness, which decreased in both 
infliximab groups and remained unchanged in 
the adalimumab group. Local side effects occurred 
only in the 2 mg infliximab group, with 42% 
developing severe uveitis that resolved under 
topical steroids or after vitrectomy. No systemic 
side effects were noticed.
Giganti et al treated two patients with 
neovascular AMD and two patients with diabetic 
macular edema with low-dose intravitreal 
infliximab (0.5 mg/0.05 ml).23 Pre-treatment of 
all four patients included anti-VEGF therapy 
and/or laser coagulation and/or photodynamic 
therapy. Only one patient with CNV and chronic 
CME secondary to AMD achieved better VA and 
remained without inflammatory side effects. The 
three other patients (one received two injections) 
showed a decrease in VA and developed vitritis 
or panuveitis. After six months, all patients 
demonstrated decreased responses on standard 
electroretinography and microperimetry. Three 
patients tested positive for human antichimeric 
antibodies. The authors deduced that low-dose 
infliximab is immunogenic, probably retinotoxic, 
and not well tolerated.
There is only one report by Theodossiadis Anti-TNF-α Therapy for Retinal Diseases; Mirshahi et al
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and coworkers describing three patients 
demonstrating improved VA after intravitreal 
infliximab for neovascular AMD. Their first 
patient had already received three injections of 
ranibizumab before undergoing an injection of 
1 mg infliximab; VA improved from 20/200 to 
20/100.24 Macular edema initially decreased by 
20%, followed by recurrence and vision loss after 
8 weeks. A second injection with 2 mg infliximab 
led to complete regression of intra- and subretinal 
fluid in conjunction with an improvement in 
vision to 20/40. After seven months, the edema 
recurred and VA dropped to 20/100. Their 
second patient received two injections of 2 mg 
infliximab two months apart after two previous 
ranibizumab injections. Vision improved from 
20/200 to 20/70 with a consecutive reduction in 
macular thickness. The last visit was two months 
after the second injection. The only observed side 
effect in this patient after the second injection 
was “vitreous opacities without inflammation”, 
which the authors attributed to a mild vitreous 
hemorrhage. Their third patient, pre-treated with 
one ranibizumab injection, also received two 
infliximab 2 mg injections, 3 months apart. VA 
increased from 20/100 to 20/30 at the last visit, 
two months after the second injection. No side 
effects were reported in patients one and three.
Current knowledge suggests that intravitreal 
TNF-α inhibitors have no permanent effect 
on macular edema in neovascular AMD or 
diabetic maculopathy. The three aforementioned 
patients showing visual improvement had short 
follow-up of only two months and markedly 
less pre-treatment than other patients and 
subjects studied by Wu et al. TNF-α inhibitors 
have been mainly used in chronic, long-lasting 
refractory disease where visual improvement is 
less likely. Dosage seems to be critical. A “safe” 
dosage of infliximab might be 1 mg/0.05 ml, 
as no inflammatory reactions were reported 
using this concentration, while lower or 
higher concentrations lead to frequent severe 
inflammatory reactions. Adalimumab 2 mg 
was well tolerated. Despite local application, 
systemic antibodies against non-human parts of 
the inhibitors have been detected, compromising 
treatment success. Thus, fully-humanized 
antibodies may solve this crucial problem. 
Current data do not support the routine 
use of intravitreal TNF-α inhibitors in any 
retinal disease outside controlled trials. Further 
investigations, particularly dose-finding studies, 
will shed light on the potential therapeutic 
benefits of intravitreal or systemic anti-TNF 
therapy for vascular and neovascular diseases 
of the choroid and retina. We await the results 
of intravitreally administered humanized 
antibodies such as adalimumab in near future.
SUMMARy AND CONCLUSION
Although the systemic use of TNF-α inhibitors 
is an appropriate off-label alternative to 
“traditional” immunosuppressive and immune-
modulatory treatments in noninfectious uveitis, 
its use in vascular and neovascular retinal 
diseases has not yet been thoroughly examined. 
While preliminary results for intravitreal 
treatment of neovascular AMD were promising, 
subsequent case reports have raised considerable 
safety concerns, particularly the occurrence 
of intraocular inflammatory responses after 
intravitreal injection of infliximab. Dose-finding 
studies and the use of humanized antibodies are 
probably crucial for the success of intravitreal 
application. Further investigations will determine 
the role of TNF-α blockers in treating diseases 
of the choroid, retina and macula.
METHOD OF LITERATURE SEARCH
Literature selection for this review was based 
on a MEDLINE database search in June 2010 
and again in June 2011 using the terms tumor 
necrosis factor, TNF, retinal disease, macular 
disease, intravitreal injection, uveitis. All 
publication years were searched, and relevant 
articles related to intravitreal injections of anti-
TNF substances were included. With regards to 
systemic use of anti-TNF drugs selected articles 
were included for this manuscript. Articles in 
foreign languages with abstracts in English 
were included as well.
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